Ⓐ
PeptiBrief
Evidence Library
randomized_controlled_trial · 2014

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation

Stanley TL|et al. · JAMA
highPMID · 25038357Trial · nct01263717Verified
View source
Plain-English summary

Tesamorelin reduced visceral fat and produced a modest liver-fat reduction in this preliminary HIV study.

Population
Adults with HIV and abdominal fat accumulation
Intervention
Tesamorelin versus placebo
Outcomes measured
Visceral adipose tissue|liver fat|metabolic measures
Key findings
Reduced visceral fat with a modest liver-fat signal.
Limitations
Relatively small and limited to people with HIV and abdominal fat accumulation.
Risk of bias
Moderate.
Citation
Stanley TL|et al. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA
Linked peptides in the PeptiBrief database
ImportantPeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.